Ginkgo Bioworks Holdings Second Quarter 2025 Results\n\nKey Financial Results\nRevenue: US$49.6m (down 12% from 2Q 2024). Net loss: US$60.3m (loss narrowed by 72% from 2Q 2024). US$1.10 loss per share (improved from US$4.23 loss in 2Q 2024).\n\nGinkgo Bioworks Holdings Revenues and Earnings Beat Expectations\nRevenue exceeded analyst estimates by 19%. Earnings per share (EPS) also surpassed analyst estimates by 30%. \n\nLooking ahead, revenue is expected to decline by 4.9% p.a. on average during the next 2 years, while revenues in the Life Sciences industry in the US are expected to grow by 5.9%. \nThe company's share price is broadly unchanged from a week ago.\n\nRisk Analysis\nYou should always think about risks. Case in point, we've spotted 2 warning signs for Ginkgo Bioworks Holdings you should be aware of.\n\nAbout NYSE:DNA\nGinkgo Bioworks Holdings\nDevelops a platform for cell programming in the United States.\nFlawless balance sheet and slightly overvalued.\n\nSimilar Companies\nNYSE:TMO - Thermo Fisher Scientific\nNYSE:DHR - Danaher\n\nMarket Insights\n🤖 The Bull and Bear Thesis on AI’s Decade of Disruption\n💥 How Agentic AI Could Change Every Industry\nWho Will Win In The Age Of Agentic AI\n\nCommunity Narratives\nA Quality Compounder Marked Down on Overblown Fears\nFair Value US$120.72 | 57.7% undervalued\nWhy Now is the Time to buy ASML\nFair Value US$1.00k | 28.0% undervalued\nWyndham Continues Global Expansion with 19% Ancillary Revenue Growth\nFair Value US$105.80 | 20.6% undervalued

Ginkgo Bioworks Holdings Second Quarter 2025 Earnings: Beats Expectations

Ginkgo Bioworks Holdings reported its second-quarter 2025 financial results, showing revenue of $49.6 million, a 12% decrease from the same period in 2024, yet exceeding analyst expectations by 19%. The company recorded a net loss of $60.3 million, a 72% improvement from the previous year, with earnings per share declining to $1.10 from $4.23 in 2024. Despite a revenue decline, the company's performance surpassed forecasts in both revenue and earnings per share. Revenue is projected to decline by 4.9% annually over the next two years, while the broader U.S. Life Sciences industry is expected to grow by 5.9%. The company's share price remained unchanged from the previous week. The article highlights two key risks and notes that Ginkgo Bioworks has a flawless balance sheet but is slightly overvalued. Similar companies mentioned include Thermo Fisher Scientific (NYSE:TMO) and Danaher (NYSE:DHR).